Terumo Heart, Inc. Reaches Clinical Milestone as the 100th Patient Worldwide Receives the DuraHeart(TM) Left Ventricular Assist System

... who are at risk of death due to end-stage left ventricular failure. The DuraHeart LVAS carries ... who are at risk of death due to end-stage left ventricular failure. We are excited to offer this ... the natural flow by pumping blood from the left ventricle to the aorta, increasing total flow to ...

Study Data Show Positive European Experience With DuraHeart Left Ventricular Assist Device for Advanced Stage Heart Failure Patients

... Mich., April 7 /PRNewswire/ -- The DuraHeart(TM) left Ventricular Assist System (LVAS) shows sustained ... first active magnetically levitated centrifugal left ventricular assist system, are published on line ... includes 68 patients who received the DuraHeart left Ventricular Assist System between January 2004 ...

David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial

... studying the new, third generation DuraHeart(TM) left Ventricular Assist System (LVAS). Dr. Feldman ... to optimize oxygenated blood flow from the left ventricle to the aorta and into the body." ... the DuraHeart is running, blood flows from the left ventricle, through the pump and directly to the ...

Terumo Heart, Inc. Reports Clinical Progress in the DuraHeart(TM) U.S. Pivotal Trial as NewYork-Presbyterian Hospital/Columbia University Medical Center Implants First Patient

... who are at risk of death due to end-state left ventricular failure. The medical team led ... the natural flow by pumping blood from the left ventricle to the aorta, increasing total flow to ... access to artificial mechanical assist devices. left Ventricular Assist Systems (LVAS) are a type of ...

SYNTAX Data Show Comparable Safety for Complex Patients Treated with TAXUS(R) Express2(TM) Stents and Bypass Surgery

... (NYSE: BSX ) today announced 12-month left main and three-vessel disease subset data from ... stents (DES) to CABG in patients with left main disease and three-vessel disease. These ... outcomes with PCI and CABG in patients with left main disease in this trial indicate PCI is a good ...

Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008

... including 12-month subset data on patients with left main (LM) and three-vessel disease (3VD) from the ... are pleased to be announcing new subset data on left main and three-vessel disease patients from the ... "Revascularization in Patients with Unprotected left Main Coronary Artery Disease," while Dr. Mohr ...

Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008

... clinical trial related to complex patients with left main and three vessel disease treated with ... drug-eluting stents to CABG in patients with left main and/or three vessel disease. ... Stent has not been established in patients with left main or three vessel disease. In the U.S., the ...

First DuraHeart(TM) Left Ventricular Assist System Implanted in the U.S. Pivotal Trial

... the first U.S. implant of the DuraHeart(TM) left Ventricular Assist System (LVAS) took place on ... DuraHeart is the world's first third generation left ventricular assist system combining a centrifugal ... who are at risk of death due to end-stage left ventricular heart failure. Yoshifumi Naka, M.D., ...

First U.S. Patient to Receive New Heart-Assist Device Doing Well After Surgery at University of Michigan

... the body, taking over most of the function of the left side of a severely weakened heart. As a result, ... the surgeon diverts blood flow from the ailing left ventricle of the heart into a titanium tube that ... the ascending aorta. By assisting the weak left ventricle, which is the heart chamber ...

New Data Offers Insights Into the Potential Role for TYKERB(R) (Lapatinib) in Non-Cytotoxic Chemotherapy-Based Treatment Regimens

... decrease (greater than or equal to 20 percent) in left ventricular ejection fraction (LVEF) that was ... events of Grade 1 or 2. Two Grade 2 asymptomatic left ventricular ejection fraction decreases, one ... has been associated with reports of decreases in left ventricular ejection fraction (LVEF). Caution ...

Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial

... coronary artery occlusion would preserve left ventricular function. The primary endpoints in COR-0002 were left ventricular diastolic relaxation indices as assessed by left ventricular pressure-volume loops and ST segment ...

Twelve DOXIL(R) Clinical Studies to be Presented at American Society of Hematology Annual Meeting

... in the VELCADE plus DOXIL arm experienced left ventricular ejection fraction decrease ... heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, ... with few or no risk factors for decreased left ventricular ejection fraction. There have ...

Myocor Receives Approval for Percutaneous Trial

... functional mitral regurgitation and reshape the left ventricle to provide a more complete reshaping ... intellectual property related to mitral valve and left ventricle reshaping. "We have been very ... for functional mitral regurgitation (FMR) and left ventricular (LV) dysfunction. About the ...

New Risk Factor for Heart Disease Identified in Very Young Children, According to Study at American Heart Association Scientific Sessions

... blood pressure and insulin levels, increased left ventricular mass and left atrial size, and other ... children at least partially reversed elevated left ventricular mass, a known risk factor for heart ... at higher risk of heart disease due to increased left ventricular mass. "There is a very clear picture ...

New Data Shows Ongoing Benefits of Percutaneous MitraClip(R) Device for Patients With Mitral Regurgitation

... significantly improved function of the left ventricle (commonly known as reverse remodeling), ... Significant Reverse Remodeling of the left Ventricle -- 12 months after a successful ... significant reverse remodeling of the left ventricle was demonstrated. Reverse remodeling ...

ECLIPSE Data on Effects of Otsuka's Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients' Hemodynamics and Urine Output Featured in Heart Failure Society of America's Late Breaking Trials

... and an estimate of the filling pressures of the left side of the heart. Compared with placebo, each ... IV) for at least three months duration due to left ventricular systolic dysfunction and who had a left ventricular ejection fraction (LVEF) of ...

Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September

... Trial results for the company's DuraHeart(TM) left Ventricular Assist System (LVAS) will be ... are at risk of death due to end-stage left ventricular failure. It is the only approved implantable left Ventricular Assist System combining a centrifugal ...

New Heart Ultrasound Research Reveals Life-Saving Treatment Alternatives and Advancements for Heart Patients

... result in comparable improvements in radial strain, strain rate and left ventricular ejection fraction in elderly patients with severe symptomatic ... can use echocardiograms, or heart ultrasound, to view the heart's left ventricular end systolic volume (this measurement refers to the volume of ...

vProtect(TM) Luminal Shield Stabilizes Vulnerable Plaque

... woman, was treated six months earlier for a culprit lesion in the left anterior descending coronary artery. At that time the SECRITT ... of imaging techniques, also located a vulnerable plaque in the patient's left circumflex artery. The lesion was unremarkable by angiography (37% ...

SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease

... Paclitaxel-Eluting Coronary Stent System to CABG surgery in patients with left main disease and/or significant narrowing of all three coronary arteries ... the TAXUS Express2 Stent System have not been established in patients with left main or three-vessel disease. Boston Scientific is a worldwide ...

Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery

... will undergo surgery to remove the tumour or tumours.(6) However, if left untreated after surgery, almost 50% of all patients suffer a relapse ... with GIST, a mutation in the DNA causes KIT to be continuously activated. left 'on' all the time, KIT signals to cells to constantly grow and divide, ...

HeartWare International Clinical Trial Shows 90% Survival at 180 Days

... updated results for its international clinical trial of the HeartWare(R) left Ventricular Assist System. The results were presented by Dr. Martin ... develops and manufactures miniaturized implantable heart pumps, or left Ventricular Assist Devices (LVADs), to treat patients suffering from ...

University of Redlands Student Cody Unser Documentary Run to Start Today in L.A.

... the story of Unser who was struck with Transverse Myelitis at age 12 and left paralyzed. *Screenings will be held in L.A. through April 23. After ... short and her legs numb during a school basketball game. It hit fast, and left Unser, of Albuquerque, paralyzed from the chest down. However, she ...

SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease

... Paclitaxel-Eluting Coronary Stent System to CABG in patients with left main disease and/or significant narrowing of all three coronary arteries ... the TAXUS Express2 Stent System have not been established in patients with left main or three-vessel disease. Boston Scientific is a worldwide ...

New England Journal of Medicine Publishes Results from Boston Scientific's Landmark SYNTAX(TM) Trial

... controlled clinical trial to compare these two treatments in patients with left main disease and three-vessel disease. These patient groups are typically ... with bifurcations, 22 percent with total occlusions and 39 percent with left main disease. The final one-year results published today showed ...

New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial with Multaq(R) (dronedarone) in Atrial Fibrillation

... factor (hypertension, diabetes, previous ischemic cerebrovascular event, left atrium size greater than 50 mm or left ventricular ejection fraction lower than 40 percent). Patients with ...

Implantable Defibrillators Lower Risk of Death in Older Heart Patients

... damaged heart muscle that results in diminished pumping action --- called left ventricular systolic dysfunction --- are candidates for ICDs to prevent ... prevention study recruited 986 consecutive patients who had diminished left ventricular function --- meaning the pumping chamber of the heart was ...

Continued Overall Survival Advantage Reported From Pivotal Trial of VELCADE(R) (Bortezomib) for Injection Based Therapy in Patients With Previously Untreated Multiple Myeloma

... or exacerbation of congestive heart failure, and new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with no risk factors for decreased left ventricular ejection fraction. There have been reports of acute diffuse ...

Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders

... such as reducing bruising and unnecessary bleeding that can result if left untreated." Types of thrombocytopenia, a blood disorder with 50 ... bleeding in the mouth, and rash-like spots on the skin. If left untreated, thrombocytopenia can become a life-threatening condition when ...

Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation

... risk factor (hypertension, diabetes, previous cerebrovascular event, left atrium size greater than 50 mm or left ventricular ejection fraction lower than 40 percent). Patients with ...

TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program

... the overall sample and in diabetic patients were renal disease, treated left main disease and congestive heart failure. "Our extensive ARRIVE ... the following patient and lesion characteristics: vein graft, left main, bifurcation, severe calcification, cardiogenic shock, direct ...

SCAI: SYNTAX Data Show PCI Is a Good Option for Patients With Complex Coronary Artery Disease

... (SCAI). The one-year results of SYNTAX also show that most patients with left main and multi-vessel disease who undergo angioplasty and stenting will ... surgery after one year. "Starting today, I can tell my patients with left main and multi-vessel disease that angioplasty and drug-eluting stents are ...

Discharge of First U.S. DuraHeart(TM) Patient

... the discharge of the first U.S. patient implanted with the DuraHeart(TM) left Ventricular Assist System (LVAS). The patient was discharged home on ... PhD, Chief Executive Officer for Terumo Heart, Inc. Earlier generation left Ventricular Assist devices are prone to hemolysis, blood clots and ...

Terumo Heart Obtains IRB Approval from the University of Michigan to Initiate DuraHeart(TM) Left Ventricular Assist System U.S. Pivotal Trial

... (IRB) at the University of Michigan to move forward with the DuraHeart(TM) left Ventricular Assist System (LVAS) U.S. Pivotal Trial for a ... cardiac support for patients who are at risk of death due to end-stage left ventricular failure. It is currently the only CE marked implantable LVAS ...

Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma

... or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute ...

VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma

... or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute ...

ATHENA Clinical Results with Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress

... risk factor (hypertension, diabetes, previous cerebrovascular event, left atrium size greater than 50 mm or left ventricular ejection fraction lower than 40 percent). Patients suffering ...

ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress

... risk factor (hypertension, diabetes, previous cerebrovascular event, left atrium size greater than 50 mm or left ventricular ejection fraction lower than 40 percent). Patients suffering ...

New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma

... or exacerbation of congestive heart failure, and/or new onset of decreased left ventricular ejection fraction has been reported, including reports in patients with few or no risk factors for decreased left ventricular ejection fraction. There have been rare reports of acute ...

GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)

... patient in the TYKERB monotherapy arm experienced symptomatic decreases in left ventricle ejection fracture (LVEF); one patient in the TYKERB + ... overexpression, TYKERB has been associated with reports of decreases in left ventricular ejection fraction (LVEF). Caution should be taken if TYKERB is ...